Target Validation Information
TTD ID	T79068
Target Name	Bacterial Fatty acid synthetase I (Bact inhA)
Type of Target	Successful
Drug Potency against Target	Isoniazid	Drug Info	IC50 = 0.01~C0.2 g/ml	[6]
	Pyrazinamide	Drug Info	IC50 = 20~100 g/ml	[6]
	(4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone	Drug Info	IC50 = 14110 nM	[1]
	(4-benzylpiperidin-1-yl)(3-chlorophenyl)methanone	Drug Info	IC50 = 7740 nM	[1]
	(4-benzylpiperidin-1-yl)(m-tolyl)methanone	Drug Info	IC50 = 7390 nM	[1]
	(4-benzylpiperidin-1-yl)(p-tolyl)methanone	Drug Info	IC50 = 5160 nM	[1]
	(4-phenylpiperazin-1-yl)(p-tolyl)methanone	Drug Info	IC50 = 16640 nM	[1]
	2-(2-aminophenoxy)-5-hexylphenol	Drug Info	Ki = 1 nM	[3]
	2-(3-aminophenoxy)-5-hexylphenol	Drug Info	Ki = 1 nM	[3]
	2-(4,6-dimethoxypyrimidin-2-yloxy)-5-hexylphenol	Drug Info	Ki = 1 nM	[3]
	2-(4-aminophenoxy)-5-hexylphenol	Drug Info	Ki = 1 nM	[3]
	2-(4-hexyl-2-methoxyphenoxy)pyrimidine	Drug Info	Ki = 1 nM	[3]
	2-bromo-4-methylphenyl 2-nitrobenzoate	Drug Info	IC50 = 9550 nM	[4]
	2-Hexadecynoic acid	Drug Info	Ki = 2100 nM	[5]
	2-nitro-N-(2,4,5-trichlorophenyl)benzamide	Drug Info	IC50 = 12020 nM	[4]
	4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide	Drug Info	IC50 = 19950 nM	[4]
	5-hexyl-2-(2-nitrophenoxy)phenol	Drug Info	Ki = 1 nM	[3]
	5-hexyl-2-(3-nitrophenoxy)phenol	Drug Info	Ki = 1 nM	[3]
	5-hexyl-2-(4-nitrophenoxy)phenol	Drug Info	Ki = 1 nM	[3]
	5-hexyl-2-(pyrazin-2-yloxy)phenol	Drug Info	Ki = 1 nM	[3]
	5-hexyl-2-(pyridin-2-yloxy)phenol	Drug Info	Ki = 1 nM	[3]
	5-hexyl-2-(pyridin-3-yloxy)phenol	Drug Info	Ki = 1 nM	[3]
	5-hexyl-2-(pyridin-4-yloxy)phenol	Drug Info	Ki = 1 nM	[3]
	5-hexyl-2-(pyrimidin-2-yloxy)phenol	Drug Info	Ki = 1 nM	[3]
	5-hexyl-2-phenoxyphenol	Drug Info	Ki = 1 nM	[3]
	5-octyl-2-phenoxyphenol	Drug Info	Ki = 1 nM	[2]
	N-(2,4-dichlorophenyl)-2-nitrobenzamide	Drug Info	IC50 = 19950 nM	[4]
	N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide	Drug Info	IC50 = 8710 nM	[4]
	N-(2,4-dimethylphenyl)-2-nitrobenzamide	Drug Info	IC50 = 10470 nM	[4]
	N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide	Drug Info	IC50 = 13800 nM	[4]
	N-(2-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide	Drug Info	Ki = 1 nM	[3]
	N-(3,5-dichlorophenyl)-2-nitrobenzamide	Drug Info	IC50 = 6170 nM	[4]
	N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide	Drug Info	IC50 = 7080 nM	[4]
	N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide	Drug Info	IC50 = 1350 nM	[4]
	N-(3-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide	Drug Info	Ki = 1 nM	[3]
	N-(4-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide	Drug Info	Ki = 1 nM	[3]
	N-(4-(diethylamino)phenyl)-2-nitrobenzamide	Drug Info	IC50 = 4370 nM	[4]
References
REF 1	Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007 Nov 1;15(21):6649-58.
REF 2	Natural products, small molecules, and genetics in tuberculosis drug development. J Med Chem. 2008 May 8;51(9):2606-12.
REF 3	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33.
REF 4	Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30.
REF 5	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
REF 6	The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.